Latest:
Dr. Alberts on Unmet Needs in CRC
Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Steven T. Rosen, MD
Latest:
Dr. Rosen on the Emergence of Novel Therapies and Research With IO in Hematologic Malignancies
Steven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.
Stuart Lutzker, MD, PhD
Latest:
Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors
Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.
Sudipto Mukherjee, MD
Latest:
Dr. Mukherjee on Radioactive Iodine Treatment of Thyroid Cancer and Risk of MDS
Sudipto Mukherjee, MD, associate staff, Department of Hematology and Oncology, Cleveland Clinic, discusses a study examining the association between radioactive iodine treatment of thyroid cancer and the risk for developing myelodysplastic syndromes.
Sujana Movva, MD
Latest:
Dr. Movva on Molecular Profiling in Sarcoma
Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.
Sukeshi R. Patel, MD
Latest:
Autophagy Modulation May Be a Novel Approach to Treatment of Advanced Cancers
Although prolonged autophagy can result in
cancer cell death, recent investigations suggest
that therapy-induced autophagy is a reversible
response that promotes cancer cell survival, and
thus may diminish the efficacy of some therapeutic
agents.
Suman Kambhampati, MD
Latest:
Dr. Kambhampati on Interferon and Novel Agents in MPNs
Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon and emerging novel agents in the treatment of patients with myeloproliferative neoplasms.